Giovanni Scribano

Dr. Giovanni Scribano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2025 in La radiologia medica
Verified
Journal Article
Open access
PDF file
Luca UrsoLuca Urso
Luca Urso
LMLuigi Manco
Luigi Manco
CCCorrado Cittanti
Corrado Cittanti
SASara Adamantiadis
Sara Adamantiadis
KSKlarisa Elena Szilagyi
Klarisa Elena Szilagyi
MGMelchiore Giganti
Melchiore Giganti
Purpose: Build machine learning (ML) models able to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients based on conventional and radiomic signatures extracted from baseline [18F]FDG PET/CT. Material and methods: Primary tumor and the most significant lymph node metastasis were manually segmented in baseline [18F]FDG PET/CT of 52 newly diagnosed BC patients. Clinical parameters, NAC and conventional semiquantitative PET parameters were collected. The standard of reference considered was surgical pCR after NAC (ypT0;ypN0). Eight-hundred-fifty-four radiomic features (RFts) were extracted from both PET and CT datasets, according to IBSI; robust RFTs were selected. The cohort was split in training (70%) and validation (30%) sets. Four ML Models (Clinical Model, CT Model, PET Model_T and PET Model_T + N) each one with 3 learners (Random Forest (RF), Neural Network and Stochastic Gradient Descendent) were trained and tested using RFts and clinical signatures. PET Models were built considering robust RFTs extracted from either primary tumor alone (PET Model_T) or also including the reference lymph node (PET Model_T + N). Results: 72 pathological uptakes (52 primary BC and 20 lymph node metastasis) at [18F]FDG PET/CT were segmented. pCR occurred in 44.2% cases. Twelve, 46 and 141 robust RFts were selected from CT Model, PET Model_T and PET Model_T + N, respectively. PET Models showed better performance than CT and Clinical Models. The best performances were obtained by the RF algorithm of the PET Model_T + N (AUC = 0.83;CA = 0.74;TP = 78%;TN = 72%). Conclusion: ML models trained on PET/CT radiomic features extracted from primary BC and lymph node metastasis could concur in the prediction of pCR after NAC and improve BC management.

15 June 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Luca UrsoLuca Urso
Luca Urso
CCCorrado Cittanti
Corrado Cittanti
LMLuigi Manco
Luigi Manco
NONaima Ortolan
Naima Ortolan
FBFrancesca Borgia
Francesca Borgia
MBMirco Bartolomei
Mirco Bartolomei
Oligometastatic patients at [18F]F-Fluorocholine (18F-choline) PET/CT may be treated with metastasis-directed therapy (MDT). The aim of this study was to combine radiomic parameters extracted from 18F-choline PET/CT and clinical data to build machine learning (ML) models able to predict MDT efficacy. Methods: Oligorecurrent patients (≤5 lesions) at 18F-choline PET/CT and treated with MDT were collected. A per-patient and per-lesion analysis was performed, using 2-year biochemical recurrence (BCR) after MDT as the standard of reference. Clinical parameters and radiomic features (RFts) extracted from 18F-choline PET/CT were used for training five ML Models for both CT and PET images. The performance metrics were calculated (i.e., Area Under the Curve—AUC; Classification Accuracy—CA). Results: A total of 46 metastases were selected and segmented in 29 patients. BCR after MDT occurred in 20 (69%) patients after 2 years of follow-up. In total, 73 and 33 robust RFTs were selected from CT and PET datasets, respectively. PET ML Models showed better performances than CT Models for discriminating BCR after MDT, with Stochastic Gradient Descent (SGD) being the best model (AUC = 0.95; CA = 0.90). Conclusion: ML Models built using clinical parameters and CT and PET RFts extracted via 18F-choline PET/CT can accurately predict BCR after MDT in oligorecurrent PCa patients. If validated externally, ML Models could improve the selection of oligorecurrent PCa patients for treatment with MDT.

30 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FEFabiana Esposito
Fabiana Esposito
LMLuigi Manco
Luigi Manco
Luca UrsoLuca Urso
Luca Urso
SASara Adamantiadis
Sara Adamantiadis
GSGiovanni Scribano
Giovanni Scribano
Luca FilippiLuca Filippi
Luca Filippi
Purpose: This bi-centric pilot study investigates the predictive value of pre-treatment [18F]FDG PET/CT radiomics for assessing therapy response in primary mediastinal B-cell lymphoma (PMBCL). Methods: All PMBCL patients underwent PET/CT with [18F]FDG between January 2011 and January 2022 at Policlinico Tor Vergata University Hospital of Rome (70% training and 30% internal validation cohort) and Sant’Anna University Hospital of Ferrara (external validation cohort). The Deauville score (DS) was used as a predictor of therapy response (DS1-DS3 vs. DS4/DS5). A total of 121 quantitative radiomics features (RFts) were extracted from manually segmented volumes of interest (VOIs) in PET and CT images, according to IBSI. ComBat harmonization was applied to correct the center variability of features, followed by class balancing with SMOTE. Two machine learning (ML) prediction models, the PET model and the CT model, were independently developed using robust RFts. For each ML model, two different algorithms were trained (i.e., Random Forest, RF, and Support Vector Machine, SVM) using 10-fold cross validation, tested on the internal/external validation set. Receiver operating characteristic (ROC) curves, area under the curve (AUC), classification accuracy (CA), precision (Prec), sensitivity (Sen), specificity (Spec), true positive (TP) scores, and true negative (TN) scores were computed. Results: The entire dataset was composed of 29 samples for the Rome cohort (23 from D1–D3 and 6 from D4/D5) and 9 samples for the Ferrara cohort (4 from D1–D3 and 5 from D4/D5). A total of 27 RFts were identified as robust for each imaging modality. Both the CT and PET models effectively predicted the Deauville score. The performance metrics of the best classifier (SVM) for the CT and PET models in external validation were AUC = 0.75/0.80, CA = 0.85/0.77, Prec = 0.97/0.67, Sen = 0.60/0.80, Spec = 0.98/0.75, TP = 75.0%/66.7%, and TN = 77.8%/85.7%, respectively. Conclusions: ML models trained on [18F]FDG PET/CT radiomic features in PMBLC patients could predict the Deauville score.

8 June 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
LMLuigi Manco
Luigi Manco
IPIlaria Proietti
Ilaria Proietti
GSGiovanni Scribano
Giovanni Scribano
RPRiccardo Pirisino
Riccardo Pirisino
OBOreste Bagni
Oreste Bagni
Luca FilippiLuca Filippi
Luca Filippi
The aim of this study was to develop a baseline [18F]FDG PET/CT model to predict immunotherapy response in advanced cutaneous squamous cell carcinoma (cSCC) and noninvasively determine tumor grade, thereby enhancing early patient stratification. We retrospectively analyzed 59 patients with histologically confirmed advanced cSCC submitted to immunotherapy with cemiplimab. All underwent [18F]FDG PET/CT at baseline and after approximately 12 weeks. Clinical response was assessed through PET findings integrated with clinical and dermatological evaluation, and patients were classified as responders (complete/partial metabolic response or stable disease) or non-responders (progression or toxicity-related discontinuation). Tumors were also classified as low to intermediate (G1–G2) or poorly differentiated (G3). Machine learning models (Random Forest and Extreme Gradient Boosting) were trained to predict treatment response and tumor grade. Clinical benefit was observed in 46/59 patients (77.9%), while 13 (22.1%) were non-responders. Histology showed 64.4% (n = 38) G1–G2 and 35.6% (n = 21) G3 tumors. The PET-based model best predicted clinical benefit (AUC = 0.96, accuracy = 91% cross-validation; AUC = 0.88, accuracy = 82% internal validation). For tumor grade prediction, the CT-based model achieved a higher AUC of 0.80 (accuracy 73%), whereas the PET-based model reached an AUC of 0.78 but demonstrated a slightly higher accuracy of 77%. Radiomic analysis of baseline [18F]FDG PET enables the discriminative prediction of immunotherapy response and tumor grade in advanced cSCC, with PET-based models outperforming CT-based ones.

30 June 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
ACAngelo Castello
Angelo Castello
LMLuigi Manco
Luigi Manco
Margherita CattaneoMargherita Cattaneo
Margherita Cattaneo
RORiccardo Orlandi
Riccardo Orlandi
LRLorenzo Rosso
Lorenzo Rosso
Paolo MendogniPaolo Mendogni
Paolo Mendogni
Background/Objectives: This study aimed to develop machine learning (ML) models to predict recurrence in thymoma patients using conventional and radiomic signatures extracted from preoperative [18F]FDG PET/CT. Methods: A total of 50 patients (25 males, 25 females; mean age 63.3 ± 14.2 years) who underwent thymectomy and preoperative [18F]FDG PET/CT between 2012 and 2022 were retrospectively analyzed. Radiomic analysis was performed using free-from-recurrence (FFR) status as a reference. Clinico-metabolic PET parameters were collected, and thymoma lesions were manually segmented on [18F]FDG PET/CT. A total of 856 radiomic features (RFts) were extracted from PET and CT datasets following IBSI guidelines, and robust RFts were selected. The dataset was split into training (70%) and validation (30%) sets. Two ML models (PET- and CT-based, respectively), each with three classifiers—Random Forest (RF), Support-Vector-Machine, and Tree—were trained and internally validated using RFts and clinico-metabolic signatures. Results: A total of 50 ROIs were selected and segmented. FFR was observed in 84% of our cohort. Forty-three robust RFts were selected from the CT dataset and 16 from the PET dataset, predominantly wavelet-based RFts. Additionally, three metabolic PET parameters were selected and included in the PET Model. Both the CT and PET models successfully discriminated against FFR after surgery, with the CT Model slightly outperforming the PET Model across different classifiers. The performance metrics of the RF classifier for the CT and PET models were AUC = 0.970/0.949, CA = 0.880/0.840, Precision = 0.884/0.842, Recall = 0.880/0.846, Specificity = 0.887/0.839, Sensitivity = 0.920/0.844, TP = 81.8%/83.3%, and TN = 92.9%/84.6%, respectively. Conclusions: ML-models trained on PET/CT radiomic features show promising results for predicting recurrence in patients with thymomas, which could be potentially applied in clinical practice for a better personalized treatment strategy.

19 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
FEFabiana Esposito
Fabiana Esposito
LMLuigi Manco
Luigi Manco
GUGLIELMO MANENTIGUGLIELMO MANENTI
GUGLIELMO MANENTI
LPLivio Pupo
Livio Pupo
ANAndrea Nunzi
Andrea Nunzi
MPMaria Ilaria Del Principe
Maria Ilaria Del Principe
Background: The role of PET/CT imaging in chronic lymphoproliferative syndromes (CLL) is debated. This study examines the potential of PET/CT radiomics in predicting outcomes and genetic profiles in CLL patients. Methods: A retrospective analysis was conducted on 50 CLL patients treated at Policlinico Tor Vergata, Rome, and screened, at diagnosis, with [18F]-FDG PET/CT. Potentially pathological lymph nodes were semi-automatically segmented. Genetic mutations in TP53, NOTCH1, and IGVH were assessed. Eight hundred and sixty-five radiomic features were extracted, with the cohort split into training (70%) and validation (30%) sets. Four machine learning models, each with Random Forest, Stochastic Gradient Descent, and Support Vector Machine learners, were trained. Results: Progression occurred in 10 patients. The selected radiomic features from CT and PET datasets were correlated with four models of progression and mutations (TP53, NOTCH1, IGVH). The Random Forest models outperformed others in predicting progression (AUC = 0.94/0.88, CA = 0.87/0.75, TP = 80.00%/87.50%, TN = 72.70%/87.50%) and the occurrence of TP53 (AUC = 0.94/0.96, CA = 0.87/0.80, TP = 87.50%/90.21%, TN = 85.70%/90.90%), and NOTCH1 (AUC = 0.94/0.85, CA = 0.87/0.67, TP = 80.00%/88.90%, TN = 80.00%/83.30%)mutations. The IGVH models showed poorer performance. Conclusions: ML models based on PET/CT radiomic features effectively predict outcomes and genetic profiles in CLL patients.